 Joshua Solomon
Concepts (183)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lung Diseases, Interstitial | 35 | 2023 | 495 | 9.100 |
Why?
| | Arthritis, Rheumatoid | 25 | 2023 | 1002 | 5.060 |
Why?
| | Idiopathic Pulmonary Fibrosis | 12 | 2023 | 500 | 2.590 |
Why?
| | Connective Tissue Diseases | 9 | 2022 | 71 | 2.080 |
Why?
| | Immunoglobulin A | 2 | 2020 | 166 | 1.270 |
Why?
| | Myositis | 2 | 2023 | 44 | 1.190 |
Why?
| | Autoantibodies | 8 | 2023 | 1347 | 1.010 |
Why?
| | Tomography, X-Ray Computed | 6 | 2021 | 2272 | 0.900 |
Why?
| | Lung Diseases | 2 | 2021 | 690 | 0.790 |
Why?
| | Digestive System Surgical Procedures | 1 | 2022 | 91 | 0.730 |
Why?
| | Risk Adjustment | 1 | 2021 | 76 | 0.720 |
Why?
| | Rectal Neoplasms | 1 | 2022 | 122 | 0.720 |
Why?
| | Pyridones | 3 | 2023 | 122 | 0.710 |
Why?
| | Coronary Artery Bypass | 1 | 2021 | 196 | 0.680 |
Why?
| | Coronary Disease | 1 | 2021 | 348 | 0.630 |
Why?
| | Frailty | 1 | 2021 | 113 | 0.630 |
Why?
| | Scleroderma, Systemic | 3 | 2021 | 90 | 0.620 |
Why?
| | Alveolitis, Extrinsic Allergic | 4 | 2023 | 83 | 0.610 |
Why?
| | Lung | 12 | 2023 | 3521 | 0.580 |
Why?
| | Humans | 55 | 2024 | 114045 | 0.560 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2019 | 296 | 0.550 |
Why?
| | Pneumonia, Pneumocystis | 1 | 2016 | 24 | 0.530 |
Why?
| | Vital Capacity | 7 | 2023 | 254 | 0.430 |
Why?
| | Respiratory System Agents | 1 | 2013 | 22 | 0.410 |
Why?
| | Prognosis | 6 | 2021 | 3315 | 0.410 |
Why?
| | Emphysema | 1 | 2013 | 106 | 0.410 |
Why?
| | Amino Acyl-tRNA Synthetases | 1 | 2011 | 28 | 0.360 |
Why?
| | Smoking | 2 | 2017 | 1382 | 0.350 |
Why?
| | Aged | 18 | 2021 | 18969 | 0.350 |
Why?
| | Mortality | 3 | 2021 | 283 | 0.350 |
Why?
| | Middle Aged | 21 | 2021 | 26605 | 0.330 |
Why?
| | Double-Blind Method | 3 | 2023 | 1656 | 0.310 |
Why?
| | Male | 27 | 2021 | 55396 | 0.310 |
Why?
| | Disease Progression | 5 | 2023 | 2371 | 0.300 |
Why?
| | Fibrosis | 2 | 2023 | 452 | 0.300 |
Why?
| | Pulmonary Diffusing Capacity | 3 | 2017 | 60 | 0.300 |
Why?
| | Female | 27 | 2021 | 59324 | 0.280 |
Why?
| | Kaplan-Meier Estimate | 5 | 2018 | 813 | 0.280 |
Why?
| | Lung Injury | 2 | 2024 | 192 | 0.270 |
Why?
| | Pulmonary Eosinophilia | 1 | 2006 | 25 | 0.260 |
Why?
| | Peptides, Cyclic | 3 | 2023 | 252 | 0.260 |
Why?
| | Narcotics | 1 | 2006 | 44 | 0.260 |
Why?
| | Risk Factors | 8 | 2023 | 8614 | 0.250 |
Why?
| | Immunosuppressive Agents | 2 | 2023 | 641 | 0.240 |
Why?
| | Radiation Injuries | 1 | 2006 | 128 | 0.240 |
Why?
| | Respiratory Function Tests | 6 | 2021 | 522 | 0.230 |
Why?
| | Environmental Pollutants | 1 | 2006 | 110 | 0.230 |
Why?
| | Survival Rate | 6 | 2019 | 1638 | 0.210 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2006 | 239 | 0.210 |
Why?
| | Treatment Outcome | 5 | 2023 | 9049 | 0.210 |
Why?
| | Forced Expiratory Volume | 2 | 2015 | 471 | 0.210 |
Why?
| | Immunomodulation | 1 | 2023 | 84 | 0.210 |
Why?
| | Pandemics | 4 | 2024 | 1310 | 0.200 |
Why?
| | HIV Infections | 1 | 2016 | 2453 | 0.200 |
Why?
| | Rheumatologists | 1 | 2022 | 12 | 0.200 |
Why?
| | Hypertension, Pulmonary | 1 | 2013 | 1736 | 0.200 |
Why?
| | Dyspnea | 1 | 2023 | 212 | 0.190 |
Why?
| | Therapeutic Irrigation | 1 | 2022 | 65 | 0.190 |
Why?
| | Mental Status and Dementia Tests | 1 | 2021 | 21 | 0.190 |
Why?
| | Patient Care | 1 | 2022 | 99 | 0.190 |
Why?
| | Life Expectancy | 1 | 2021 | 46 | 0.190 |
Why?
| | Cause of Death | 3 | 2019 | 362 | 0.180 |
Why?
| | Rectum | 1 | 2022 | 151 | 0.180 |
Why?
| | Serum Albumin | 1 | 2021 | 137 | 0.180 |
Why?
| | Mucin-5B | 2 | 2021 | 184 | 0.180 |
Why?
| | Aged, 80 and over | 8 | 2021 | 6306 | 0.180 |
Why?
| | Elective Surgical Procedures | 1 | 2021 | 150 | 0.170 |
Why?
| | Attitude | 1 | 2022 | 228 | 0.170 |
Why?
| | Comorbidity | 2 | 2021 | 1447 | 0.170 |
Why?
| | Geriatric Assessment | 1 | 2021 | 175 | 0.170 |
Why?
| | Hemoglobins | 1 | 2021 | 308 | 0.160 |
Why?
| | Sarcoidosis | 2 | 2011 | 133 | 0.160 |
Why?
| | Reproducibility of Results | 2 | 2023 | 2764 | 0.160 |
Why?
| | United States | 11 | 2021 | 12137 | 0.160 |
Why?
| | Acute Disease | 1 | 2021 | 907 | 0.160 |
Why?
| | Gain of Function Mutation | 1 | 2018 | 30 | 0.150 |
Why?
| | Pulmonary Fibrosis | 2 | 2012 | 321 | 0.150 |
Why?
| | Antirheumatic Agents | 1 | 2021 | 255 | 0.150 |
Why?
| | Case-Control Studies | 5 | 2021 | 3003 | 0.150 |
Why?
| | Adult | 10 | 2023 | 30375 | 0.150 |
Why?
| | Multivariate Analysis | 3 | 2016 | 1422 | 0.150 |
Why?
| | Longitudinal Studies | 3 | 2019 | 2384 | 0.140 |
Why?
| | Extracellular Traps | 1 | 2017 | 40 | 0.140 |
Why?
| | Critical Care | 1 | 2021 | 472 | 0.140 |
Why?
| | Idiopathic Interstitial Pneumonias | 1 | 2017 | 46 | 0.140 |
Why?
| | Pneumocystis carinii | 1 | 2016 | 7 | 0.140 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2022 | 850 | 0.130 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2022 | 1204 | 0.130 |
Why?
| | Common Variable Immunodeficiency | 1 | 2016 | 25 | 0.130 |
Why?
| | Pedigree | 1 | 2017 | 460 | 0.130 |
Why?
| | Survival Analysis | 2 | 2017 | 1206 | 0.130 |
Why?
| | Rheumatoid Factor | 1 | 2017 | 157 | 0.130 |
Why?
| | Granuloma | 1 | 2016 | 82 | 0.130 |
Why?
| | Health Care Costs | 1 | 2018 | 381 | 0.120 |
Why?
| | Thoracic Diseases | 1 | 2015 | 13 | 0.120 |
Why?
| | Sputum | 1 | 2017 | 286 | 0.120 |
Why?
| | Emergency Medical Services | 1 | 2021 | 581 | 0.110 |
Why?
| | Mortality, Premature | 1 | 2013 | 11 | 0.110 |
Why?
| | Quality of Life | 1 | 2023 | 2343 | 0.100 |
Why?
| | Bronchiolitis Obliterans | 1 | 2013 | 66 | 0.100 |
Why?
| | Proportional Hazards Models | 1 | 2015 | 1078 | 0.100 |
Why?
| | Diagnostic Imaging | 1 | 2015 | 278 | 0.100 |
Why?
| | Mycophenolic Acid | 1 | 2013 | 76 | 0.100 |
Why?
| | Hospitalization | 1 | 2021 | 1762 | 0.100 |
Why?
| | Bronchial Diseases | 1 | 2012 | 35 | 0.100 |
Why?
| | Histocompatibility Antigens Class II | 1 | 2013 | 350 | 0.100 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 3 | 2023 | 787 | 0.100 |
Why?
| | Antigens, Human Platelet | 1 | 2011 | 9 | 0.090 |
Why?
| | Antibodies, Antinuclear | 1 | 2011 | 58 | 0.090 |
Why?
| | Lung Transplantation | 1 | 2013 | 244 | 0.090 |
Why?
| | Diagnosis, Differential | 1 | 2014 | 1331 | 0.090 |
Why?
| | Respiratory Insufficiency | 1 | 2013 | 286 | 0.090 |
Why?
| | Risk Assessment | 1 | 2019 | 2958 | 0.090 |
Why?
| | Bleomycin | 1 | 2011 | 228 | 0.080 |
Why?
| | Biomarkers | 1 | 2019 | 3397 | 0.080 |
Why?
| | Gastroesophageal Reflux | 1 | 2012 | 229 | 0.080 |
Why?
| | Incidence | 3 | 2021 | 2314 | 0.080 |
Why?
| | Retrospective Studies | 5 | 2023 | 12521 | 0.080 |
Why?
| | Pulmonary Embolism | 1 | 2011 | 180 | 0.080 |
Why?
| | Sleep Apnea, Obstructive | 1 | 2012 | 195 | 0.080 |
Why?
| | Predictive Value of Tests | 1 | 2013 | 1791 | 0.070 |
Why?
| | Prevalence | 3 | 2021 | 2247 | 0.070 |
Why?
| | Cohort Studies | 1 | 2015 | 4883 | 0.060 |
Why?
| | Promoter Regions, Genetic | 2 | 2021 | 1131 | 0.060 |
Why?
| | Young Adult | 5 | 2021 | 10444 | 0.060 |
Why?
| | Disease Outbreaks | 1 | 2006 | 305 | 0.050 |
Why?
| | Bronchi | 1 | 2024 | 223 | 0.050 |
Why?
| | Sex Factors | 3 | 2013 | 1706 | 0.050 |
Why?
| | Anti-Citrullinated Protein Antibodies | 1 | 2023 | 90 | 0.050 |
Why?
| | Glucocorticoids | 1 | 2006 | 526 | 0.050 |
Why?
| | Polymyositis | 1 | 2021 | 15 | 0.050 |
Why?
| | Dermatomyositis | 1 | 2021 | 23 | 0.050 |
Why?
| | Public Health Surveillance | 1 | 2021 | 61 | 0.040 |
Why?
| | Sex Distribution | 2 | 2012 | 336 | 0.040 |
Why?
| | Biopsy | 2 | 2014 | 1024 | 0.040 |
Why?
| | Canada | 1 | 2021 | 320 | 0.040 |
Why?
| | Methotrexate | 1 | 2021 | 227 | 0.040 |
Why?
| | Occupations | 1 | 2019 | 35 | 0.040 |
Why?
| | Logistic Models | 2 | 2016 | 1829 | 0.040 |
Why?
| | Insurance Claim Review | 1 | 2018 | 68 | 0.040 |
Why?
| | Genomics | 1 | 2023 | 631 | 0.040 |
Why?
| | Follow-Up Studies | 2 | 2018 | 4392 | 0.040 |
Why?
| | Forecasting | 1 | 2019 | 331 | 0.040 |
Why?
| | Disease Management | 1 | 2021 | 556 | 0.030 |
Why?
| | Global Health | 1 | 2019 | 284 | 0.030 |
Why?
| | Intensive Care Units | 1 | 2021 | 614 | 0.030 |
Why?
| | Hypersplenism | 1 | 2016 | 7 | 0.030 |
Why?
| | Leukopenia | 1 | 2016 | 27 | 0.030 |
Why?
| | Adolescent | 3 | 2021 | 17800 | 0.030 |
Why?
| | Odds Ratio | 1 | 2018 | 951 | 0.030 |
Why?
| | Critical Illness | 1 | 2021 | 640 | 0.030 |
Why?
| | Arthritis | 1 | 2016 | 109 | 0.030 |
Why?
| | Alberta | 1 | 2013 | 10 | 0.030 |
Why?
| | Age Factors | 2 | 2011 | 2885 | 0.030 |
Why?
| | Radiography | 1 | 2016 | 803 | 0.030 |
Why?
| | Genotype | 1 | 2018 | 1757 | 0.030 |
Why?
| | Medicare | 1 | 2018 | 661 | 0.030 |
Why?
| | Severity of Illness Index | 1 | 2021 | 2537 | 0.030 |
Why?
| | Cross-Sectional Studies | 1 | 2023 | 4402 | 0.030 |
Why?
| | Patient Dropouts | 1 | 2013 | 66 | 0.030 |
Why?
| | Pulmonary Gas Exchange | 1 | 2012 | 117 | 0.020 |
Why?
| | Databases, Factual | 1 | 2016 | 1125 | 0.020 |
Why?
| | Lung Compliance | 1 | 2011 | 47 | 0.020 |
Why?
| | Chemokine CXCL1 | 1 | 2011 | 67 | 0.020 |
Why?
| | Trauma Severity Indices | 1 | 2011 | 108 | 0.020 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2012 | 507 | 0.020 |
Why?
| | Poisson Distribution | 1 | 2010 | 71 | 0.020 |
Why?
| | Genetic Predisposition to Disease | 1 | 2018 | 2090 | 0.020 |
Why?
| | Age Distribution | 1 | 2011 | 341 | 0.020 |
Why?
| | Chi-Square Distribution | 1 | 2011 | 492 | 0.020 |
Why?
| | Pregnancy | 1 | 2021 | 5499 | 0.020 |
Why?
| | Collagen | 1 | 2011 | 414 | 0.020 |
Why?
| | Bronchoalveolar Lavage Fluid | 1 | 2011 | 580 | 0.020 |
Why?
| | Transforming Growth Factor beta | 1 | 2011 | 445 | 0.020 |
Why?
| | Risk | 1 | 2011 | 810 | 0.020 |
Why?
| | Regression Analysis | 1 | 2010 | 945 | 0.020 |
Why?
| | Chronic Disease | 1 | 2013 | 1577 | 0.020 |
Why?
| | Sex Characteristics | 1 | 2011 | 636 | 0.020 |
Why?
| | Time Factors | 1 | 2013 | 6077 | 0.010 |
Why?
| | Mice, Inbred C57BL | 1 | 2011 | 4680 | 0.010 |
Why?
| | Prospective Studies | 1 | 2012 | 6195 | 0.010 |
Why?
| | Mice | 1 | 2011 | 14843 | 0.010 |
Why?
| | Animals | 1 | 2011 | 31565 | 0.010 |
Why?
|
|
Solomon's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|